von Hippel-Lindau (VHL) disease is a hereditary cancer with a predilection for the central nervous system and retina.
The von Hippel-Lindau tumor suppressor gene is mutated in families with von Hippel-Lindau disease and encodes a protein (VHL) of 213 amino acids with an acidic pentapeptide motif in the N-terminus.
Mutations in the VHL gene result in constitutive expression of many hypoxi-induced genes, at least in part because of increases in the cellular level of hypoxia-inducible transcription factor HIF-1α.
VHL protein binds to elongin B, elongin C, and Cul2 to form a stable complex that targets hypoxia inducibal factors (HIFs) for degradation and transcriptional regulation.
In addition, VHL protein has also been shown to interact with specific protein kinase C isoforms, histone deacetylases and HIF-1 inhibitor (FIH-1).
α-VHL is an affinity-purified rabbit polyclonal antibody raised against the recombinant VHL protein.
Applications:Suitable for use in ELISA, Western Blot.
Other applications not tested.
Recommended Dilution:Western Blot: 1:200-1:1000Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50?.
Freeze at -20°C.
Aliquots are stable for at least 12 months at -20°C.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Further dilutions can be made in assay buffer.
仕様
Size：50ug
Host：rabbit
Purity：As reported
Form：Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide.
Specificity：α-VHL reacts with the VHL protein in HeLa nuclear extract by Western blotting.
